Alendronate sodium oral solution patent?

Alendronate Sodium Oral Solution Patent Information

When Does Exclusivity Expire?

The patent for Alendronate sodium oral solution, also known as oral solution form of Fosamax, [1] has expired. Alendronate sodium was first approved in 2001, and its oral solution was introduced in later years [2]. The patents covering the oral solution form of Alendronate sodium have now expired, allowing generic versions to enter the market.

What Companies Manufacture Fosamax Oral Solution?

Fosamax oral solution is currently manufactured by Merck & Co., Inc. [3] Although the patent has expired, Merck maintains market exclusivity under Hatch-Waxman provisions [4].

Can Biosimilars Enter Before Patent Expiry?

Biosimilars cannot enter the market before patent expiry. However, once the Alendronate sodium patent expires, biosimilar companies can submit abbreviated Biologics License Applications (aBLAs) to the FDA, enabling them to market their biosimilars [5].

How Does This Affect Patient Access?

The expiration of the patent for Alendronate sodium oral solution will likely lead to increased competition in the market, contributing to lower prices and better access for patients [6]. Additionally, the FDA's biosimilar approval process is intended to promote competition and lower costs for patients.

Sources:

[1] DrugPatentWatch.com, 'Patent Expiration for Fosamax Oral Solution'
[2] Merck & Co., Inc. press release
[3] FDA, 'Fosamax Oral Solution Approval'
[4] Hatch-Waxman Act
[5] FDA, 'Biosimilar Approvals'
[6] Center for Medicare & Medicaid Services, 'Biosimilars'